The Global Biosimilars Market was valued at USD 5237.0 currently and is projected to reach USD 28200.0 million by 2020, at a CAGR of 40.3% during the forecast period from 2015 to 2021.

The factors that are contributing to the growth of this market are the intended reductions in the healthcare expenditure, cost-effectiveness of biosimilar drugs, and the increasing number of off-patented drugs whose total sales in the year 2013 was USD 9.1 billion will expire in 2018 and 2016 in the EU and the US, respectively. Similarly, six such multi-billion drugs will expire in coming five years. Other than these, the rising demand for biosimilars is also another driving force for the biosimilars market.

However, there are factors that are restraining the growth of this market, such as the different regulatory frameworks and requirements in different countries and high manufacturing complexities, since the manufacturing of biosimilars requires sophisticated technologies. Although, small scale production is quite possible, but there is a risk involved in the scaling-up of the production. This brings forward the concern of operating on a large scale.

The major players of this market are Sandoz, Dr. Reddys, Teva Pharmaceuticals, Hospira, Bioton, Biocon, Sun-Ranbaxy, Zydus Cadila, Synthon, and Celltrion. This report offers comprehensive profiles of these companies composed of their business strategy for biosimilars.